Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
Código da empresaBHVN
Nome da EmpresaBiohaven Ltd
Data de listagemSep 23, 2022
Fundado em2022
CEODr. Vlad Coric, M.D.
Número de funcionários256
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 23
Endereço215 Church Street
CidadeNEW HAVEN
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal06510
Telefone12034040410
Sitehttps://www.biohaven.com/
Código da empresaBHVN
Data de listagemSep 23, 2022
Fundado em2022
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados